Considering that a high RBBP8 methylation frequency correlates with increased survival of BLCA patients, RBBP8 methylation might be a potential biomarker for better therapy response in such subsets of patients; however, further investigation is necessary to validate this hypothetical notion. This evidence concerns the gene RBBP8 and bladder transitional cell carcinoma.